Gilead Sciences (GILD) free cash flow

Free cash flow · fiscal 2025
$9.46B

Gilead Sciences (GILD) generated free cash flow of $9.46B in fiscal 2025 (the year ended December 31, 2025). That is 8.2% lower than the $10.31B of fiscal 2024. Figures as of 18 Nov 2026, 12:49 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$9.46B
Change on fiscal 2024
−8.2%
Growth, 5 years
+4.7% a year
Growth, 10 years
−7.4% a year
Highest on record
$20.50Bfiscal 2015
Lowest on record
$1.59Bfiscal 2007
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Gilead Sciences free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 4.7% a year; over ten years the rate was −7.4% a year. Across the 19 fiscal years on record (2007–2025), the highest was $20.50B in fiscal 2015 and the lowest $1.59B in fiscal 2007.

History · 19 fiscal years

Free cash flow by fiscal year

Gilead Sciences free cash flow, year by year

Gilead Sciences (GILD) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$9.46B 8.2% down
2024$10.31B 38.9% up
2023$7.42B 11.1% down
2022$8.34B 22.8% down
2021$10.81B 43.7% up
2020$7.52B 9.6% down
2019$8.32B 11.3% up
2018$7.48B 33.9% down
2017$11.31B 30.6% down
2016$16.30B 20.5% down
2015$20.50B 67.2% up
2014$12.26B 312.7% up
2013$2.97B 6.2% up
2012$2.80B 20.2% down
2011$3.51B 26.5% up
2010$2.77B 2.7% down
2009$2.85B 40.5% up
2008$2.03B 27.5% up
2007$1.59B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Gilead Sciences and comparable companies
CompanyFree cash flowFiscal year
Thermo Fisher Scientific TMO$6.29B2025
Amgen AMGN$8.10B2025
Gilead Sciences GILD$9.46B2025
Abbott Laboratories ABT$7.40B2025
Novo Nordisk NVODKK 28.99B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on GILD

Gilead Sciences, figure by figure

Gilead Sciences (GILD) overview: price, valuation and scorecardAll health care companies by market value

Gilead Sciences free cash flow: questions and answers

What is Gilead Sciences's free cash flow?

Gilead Sciences (GILD) generated free cash flow of $9.46B in fiscal 2025 (the year ended December 31, 2025). That is 8.2% lower than the $10.31B of fiscal 2024.

What is the growth rate of Gilead Sciences's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 4.7% a year; over ten years the rate was −7.4% a year.

What are the highest and lowest free cash flow figures on record for Gilead Sciences?

Across the 19 fiscal years on record (2007–2025), the highest was $20.50B in fiscal 2015 and the lowest $1.59B in fiscal 2007.

How is Gilead Sciences's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Gilead Sciences it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Gilead Sciences (GILD) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/GILD/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.